Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Regulus Therapeutics is a biotechnology business based in the US. Regulus Therapeutics shares (RGLS) are listed on the NASDAQ and all prices are listed in US Dollars. Regulus Therapeutics employs 27 staff and has a trailing 12-month revenue of around $5 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.79 |
|---|---|
| 52-week range | $0.76 - $3.70 |
| 50-day moving average | $1.37 |
| 200-day moving average | $1.67 |
| Wall St. target price | $10.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.89 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.7929 from 2023-03-27
| 1 week (2023-03-22) | -23.76% |
|---|---|
| 1 month (2023-03-01) | -41.27% |
| 3 months (2022-12-29) | -41.70% |
| 6 months (2022-09-29) | -54.95% |
| 1 year (2022-03-29) | 173.41% |
|---|---|
| 2 years (2021-03-29) | -42.96% |
| 3 years (2020-03-27) | 66.23% |
| 5 years (2018-03-28) | 87.36 |
| Revenue TTM | $5 million |
|---|---|
| Gross profit TTM | $-17,794,000 |
| Return on assets TTM | -37.13% |
| Return on equity TTM | -83.46% |
| Profit margin | 0% |
| Book value | $2.36 |
| Market capitalisation | $17.5 million |
TTM: trailing 12 months
We're not expecting Regulus Therapeutics to pay a dividend over the next 12 months.
Regulus Therapeutics's shares were split on a 1:10 basis on 28 June 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Regulus Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Regulus Therapeutics shares which in turn could have impacted Regulus Therapeutics's share price.
Over the last 12 months, Regulus Therapeutics's shares have ranged in value from as little as $0.76 up to $3.699. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regulus Therapeutics's is 1.645. This would suggest that Regulus Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Regulus Therapeutics Inc. , a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California. .
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.